▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #78 by analyst upside · 2026-09-28
NRXP
NRx Pharmaceuticals, Inc.
Healthcare · Market Cap $130M · P/E 0x
ANALYST PRICE TARGET
+1177.1%
implied upside to consensus target
Current Price $3.0
Consensus Target $38.25
Bull Target $49.0
Bear Target $10.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $1.62
52-Week High $5.05
YTD Return +14.3%
FUNDAMENTALS
Market Cap $130M
P/E Ratio (TTM) N/A
Forward P/E 6.0x
EPS (TTM) $-0.51
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $3M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.62
52-Week High $5.05
Current Price $3.0
Bear Target $10.0
Bull Target $49.0
● Now $3.0 ● Target $38.25
TRADING DATA
Avg Volume 892K
YTD Return +14.3%
Analyst Count 4
Consensus Buy
Upside to Target +1177.1%
Last Updated 2026-09-28

ANALYST SUMMARY

NRx Pharmaceuticals, Inc. (NRXP) is currently trading at $3.0 with a Wall Street consensus price target of $38.25, implying potential upside of 1177.1% over the next 12 months. 4 analysts currently cover NRXP, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $49.0, while the most cautious has a target of $10.0.

NRXP operates in the Healthcare sector with a market capitalisation of $130M. The stock is up 14.3% year-to-date and is currently trading near the lower end of its 52-week range of $1.62 – $5.05.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for NRXP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG reit
Buy → Buy 2026-09-14 38% win rate (8 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-08-25 31% win rate (48 calls)
BTIG reit
Buy → Buy 2026-08-18 38% win rate (8 calls)
BTIG - Reiterated
Buy → Buy 2026-08-07 38% win rate (8 calls)
D. Boral Capital - Reiterated
Buy → Buy 2026-05-05 32% win rate (25 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-04-27 31% win rate (48 calls)
Ascendiant Capital - Reiterated
Buy → Buy 2026-04-27 Building track record
D. Boral Capital - Reiterated
Buy → Buy 2026-04-23 32% win rate (25 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →